State Street
SGMT icon

State Street’s Sagimet Biosciences SGMT Stock Holding History

State Street’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$673K Buy
128,788
+11,400
+10% +$63.5K ﹤0.01% 3581
2025
Q4 		$695K Buy
117,388
+6,900
+6% +$49.6K ﹤0.01% 3604
2025
Q3 		$758K Buy
110,488
+10,688
+11% +$86.7K ﹤0.01% 3574
2025
Q2 		$760K Hold
99,800
– – ﹤0.01% 3543
2025
Q1 		$325K Buy
99,800
+15,700
+19% +$65.9K ﹤0.01% 3707
2024
Q4 		$378K Buy
84,100
+29,900
+55% +$151K ﹤0.01% 3696
2024
Q3 		$150K Hold
54,200
– – ﹤0.01% 3885
2024
Q2 		$185K Sell
54,200
-229,152
-81% -$1.05M ﹤0.01% 3845
2024
Q1 		$1.54M Buy
283,352
+202,700
+251% +$1.46M ﹤0.01% 3363
2023
Q4 		$437K Buy
80,652
+50,076
+164% +$236K ﹤0.01% 3670
2023
Q3 		$269K Buy
+30,576
New +$407K ﹤0.01% 3847

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street's SGMT Position: Q1 2026 in Review

State Street increased its Sagimet Biosciences (SGMT) stake by 9.7% in Q1 2026, buying an estimated $63.5K and bringing the position to 128,788 shares worth $673K. The position accounts for ﹤0.01% of the portfolio, ranked #3581.

State Street first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.54M in Q1 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • State Street held 128,788 shares of Sagimet Biosciences worth $673K as of Q1 2026.
  • State Street bought 11,400 Sagimet Biosciences shares in Q1 2026, an estimated $63.5K.
  • Sagimet Biosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3581 holding.
  • State Street first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • State Street's Sagimet Biosciences position peaked at $1.54M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.